Merck acquires CN201 from Curon Biopharmaceutical for $700M cash and $600M milestones, targeting B-cell associated diseases.

Merck & Co. has agreed to acquire CN201, a clinical-stage bispecific antibody targeting B-cell associated diseases, from privately-held Curon Biopharmaceutical for $700 million in cash, with an additional $600 million in potential milestone payments. CN201 is currently being evaluated in Phase 1 and Phase 1b/2 trials for relapsed or refractory non-Hodgkin's lymphoma and B-cell acute lymphocytic leukemia. Merck plans to evaluate CN201 for B-cell malignancies and explore its potential for treating autoimmune diseases. The acquisition aims to support the potential of treating autoimmune diseases.

August 09, 2024
12 Articles